Spots Global Cancer Trial Database for erbb1
Every month we try and update this database with for erbb1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | NCT00251433 | Neoplasms, Brea... | lapatinib, doce... | 18 Years - | Novartis | |
GW572016 In Patients With Advanced Or Metastatic Breast Cancer | NCT00462956 | Neoplasms, Brea... | Tykerb | 20 Years - 40 Years | GlaxoSmithKline | |
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | NCT00272987 | Neoplasms, Brea... | lapatinib paclitaxel trastuzumab | 18 Years - | Novartis | |
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis | |
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer | NCT00320411 | Neoplasms, Brea... | lapatinib | 20 Years - 74 Years | GlaxoSmithKline | |
GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer | NCT00371488 | Neoplasms, Brea... | GW572016 oral t... | 20 Years - 74 Years | GlaxoSmithKline | |
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis |